Reason for request
Inclusion on the list of medicines reimbursed by National Health Insurance and approved for use by hospitals.
Clinical Benefit
| Substantial |
The actual benefit of RANEXA in this indication is substantial. |
Clinical Added Value
| no clinical added value |
RANEXA should be used only by patients with stable angina that is inadequately controlled or who are intolerant to betablockers and/or calcium channel blockers.
Given the data available, RANEXA does not provide any improvement in actual benefit (IABV) in the management of these patients. |
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
6frK0C0EZm9B4QgC
